DBD (Diebold Nixdorf, Incorporated) — AI Stock Analysis & Recommendation
Research of August 4, 2026 · Technology / Calculating & Accounting Machines (No Electronic Computers)
TradeFlare's AI research teams rate DBD a BUY. The latest price is $65.19.
The research plan
- Entry: $74.18
- Target: $83.05
- Stop: $66.76
- Time horizon: weeks
The insider buying is a strong signal, but the technicals and risk profile suggest a longer-term accumulation play.
Why
The insider buying is a strong signal, but the technicals and risk profile suggest a longer-term accumulation play. Catalysts to watch: Significant insider buying from an executive, indicating high conviction in the company's future; Strong fundamental analysis with impressive earnings growth and attractive forward P/E; Positive analyst consensus with a substantial target price suggesting significant upside potential. Key risks: High debt levels and negative free cash flow present significant financial risk; Elevated volatility and high short interest could lead to sharp price swings; Bearish short-term technical signals and mixed momentum indicators.
What could push DBD higher
- Significant insider buying from an executive, indicating high conviction in the company's future.
- Strong fundamental analysis with impressive earnings growth and attractive forward P/E.
- Positive analyst consensus with a substantial target price suggesting significant upside potential.
Key risks for DBD
- High debt levels and negative free cash flow present significant financial risk.
- Elevated volatility and high short interest could lead to sharp price swings.
- Bearish short-term technical signals and mixed momentum indicators.
What each AI research team found
Fundamental team: Bullish · valuation: undervalued
Diebold Nixdorf is fundamentally undervalued based on its attractive forward P/E and strong earnings growth, supported by positive TTM free cash flow. While high debt is a concern, the significant analyst upside potential and operational improvements suggest a bullish outlook.
- Strong year-over-year earnings growth (34.2%) coupled with modest revenue growth (1.7%) suggests improving operational efficiency and margin expansion.
- Attractive forward P/E of 10.95x, significantly lower than trailing P/E of 25.44x, indicates substantial expected earnings growth.
- Overwhelmingly positive analyst consensus ('strong_buy') with a mean target price of $98.33 suggests significant upside potential.
Technical team: Bearish
Despite a long-term bullish trend, short-term technicals are leaning bearish. A bearish engulfing pattern and a breakdown below a key support level, combined with bearish MACD and Stochastic signals, suggest a potential downside move towards the next support. The current price near support offers a defined risk/reward scenario.
- The stock is in a sideways trend with a bearish short-term MA crossover, suggesting a potential move towards the support level of $74.18.
- The stock is trading in a sideways range with volume generally below average, suggesting a neutral outlook with potential for a move towards the lower support if bearish sentiment prevails.
- Momentum is mixed with RSI neutral, MACD bearish, and Stochastic showing a potential bearish crossover, suggesting a neutral to slightly bearish outlook near support.
Sentiment team: Neutral
The overall sentiment for Diebold Nixdorf is neutral, reflecting a balance between positive operational highlights and analyst support, and significant concerns around free cash flow and past financial restructuring. While recent news and social media sentiment are mixed, the analyst sentiment remains cautiously optimistic, suggesting a stable but unconvincing outlook.
- Diebold Nixdorf's recent news is characterized by a neutral sentiment, with Q2 earnings meeting expectations and highlighting strong retail demand, but overshadowed by a significant stock drop due to negative free cash flow concerns. (-0.021)
- Diebold Nixdorf (DBD) sentiment is neutral, with recent earnings reports showing mixed results of solid execution offset by negative free cash flow, while past bankruptcy concerns and stock volatility temper overall optimism despite positive analyst...
- Diebold Nixdorf's sentiment is neutral, balancing positive analyst ratings and strong retail demand against recent concerns over negative free cash flow and insider selling, with upcoming earnings being a near-term catalyst. (0.0)
Risk team: High
Diebold Nixdorf presents a high-risk profile due to significant leverage, high volatility, and negative free cash flow, amplified by elevated short interest. The substantial debt burden and limited interest coverage create a precarious financial situation, making it susceptible to market downturns or operational missteps. Consequently, a small position size with a strict stop-loss is recommended to manage the...
- High Leverage and Debt Levels: The company exhibits a very high debt-to-equity ratio (113.55%) and a high SEC liabilities to equity proxy (2.85), indicating significant financial strain and increased risk of default, especially with negative quarterly free...
- Elevated Volatility and Short Interest: DBD shows high realized volatility (20-day annualized 71.78%) and a high days to cover (>5), suggesting significant price swings and potential for sharp downside or short squeeze driven volatility.
- Negative Free Cash Flow: The company's latest quarterly free cash flow is negative (-$28.9 million), which, combined with high debt, poses liquidity risks if not managed effectively.
DBD at a glance
| Market value | $2.2B |
| Price / earnings | 21.3 |
| Revenue growth (year over year) | 5.4% |
| Profit margin | 2.9% |
| Debt / equity | 0.97 |
Every AI call on DBD since May 25, 2026, and what happened next (3 calls) →
Frequently asked questions
Is DBD a buy? In its research of August 4, 2026, TradeFlare's AI rated DBD a BUY. This is AI-generated research, not financial advice.
What is the price target for DBD? The research sets a target of $83.05 with a stop at $66.76.
When was this analysis last updated? August 4, 2026. Stocks on TradeFlare's lists are re-researched every market night. How the research works.
Research of August 4, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.